ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more
ValiRx plc (VAL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.179x
Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K) by net assets (£3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ValiRx plc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ValiRx plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALUMEXX N.V. NAM. EO-10
F:NE8F
|
N/A |
|
Heliogen Inc
OTCQX:HLGN
|
-0.366x |
|
Widad Group Bhd
KLSE:0162
|
-0.035x |
|
BitFuFu Inc. Warrant
NASDAQ:FUFUW
|
0.000x |
|
Major Development Public Company Limited
BK:MJD
|
-0.052x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
SYNOPSYS (SYP.SG)
STU:SYP
|
0.059x |
|
NuCana PLC
NASDAQ:NCNA
|
0.049x |
Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)
The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £3.92 Million | £-1.58 Million | -0.405x | +33.68% |
| 2023-12-31 | £2.90 Million | £-1.77 Million | -0.610x | -36.39% |
| 2022-12-31 | £3.83 Million | £-1.71 Million | -0.447x | -21.21% |
| 2021-12-31 | £3.41 Million | £-1.26 Million | -0.369x | +8.12% |
| 2020-12-31 | £4.76 Million | £-1.91 Million | -0.402x | +33.42% |
| 2019-12-31 | £2.22 Million | £-1.34 Million | -0.604x | +45.45% |
| 2018-12-31 | £3.03 Million | £-3.35 Million | -1.106x | -48.34% |
| 2017-12-31 | £3.15 Million | £-2.35 Million | -0.746x | +58.08% |
| 2016-12-31 | £2.37 Million | £-4.22 Million | -1.779x | -211.40% |
| 2015-12-31 | £4.53 Million | £-2.59 Million | -0.571x | +47.02% |
| 2014-12-31 | £2.79 Million | £-3.01 Million | -1.079x | -68.52% |
| 2013-12-31 | £3.23 Million | £-2.07 Million | -0.640x | -62.79% |
| 2012-12-31 | £5.04 Million | £-1.98 Million | -0.393x | -19.06% |
| 2011-12-31 | £4.42 Million | £-1.46 Million | -0.330x | -32.96% |
| 2010-12-31 | £2.00 Million | £-496.00K | -0.248x | +75.67% |
| 2009-12-31 | £907.00K | £-926.00K | -1.021x | -76.42% |
| 2008-12-31 | £1.37 Million | £-794.00K | -0.579x | -15.19% |
| 2007-12-31 | £1.67 Million | £-839.00K | -0.502x | -2848.55% |
| 2006-12-31 | £2.69 Million | £-45.77K | -0.017x | +95.01% |
| 2006-03-31 | £161.00K | £-55.00K | -0.342x | -210.08% |
| 2005-12-31 | £-203.00K | £-63.00K | 0.310x | -90.48% |
| 2004-12-31 | £-69.00K | £-225.00K | 3.261x | +195.24% |
| 2003-12-31 | £67.00K | £74.00K | 1.104x | +108.81% |
| 2002-12-31 | £-141.00K | £1.77 Million | -12.539x | -759.53% |
| 2001-12-31 | £1.00 Million | £1.91 Million | 1.901x | -- |